Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0

Arcturus Therapeutics announced interim Phase 2 results for ARCT-810, indicating it is generally safe and well tolerated with positive activity in urea cycle biomarkers. The company introduced LUNAR 2.0, which shows over 30-fold higher protein expression in non-human primate studies, leading to new therapeutic opportunities. Additionally, ARCT-2601, a candidate for OTC deficiency, will be integrated into the ongoing Phase 2 study by the end of 2026, as per FDA guidance. Arcturus is also acquiring myNEO, an AI discovery company, to enhance mRNA design and innovation.